[Interpretation of the 2024 American Diabetes Association guidelines for the comprehensive management of non-alcoholic fatty liver disease combined with diabetes mellitus].
W J NiJ LiY M NanPublished in: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology (2024)
Non-alcoholic fatty liver disease (NAFLD) is a common concomitant disease in adults with type 2 diabetes mellitus (T2DM) and prediabetes. Therefore, T2DM/NAFLD patient populations are at high risk for cardiovascular disease. The occurrence and progression of non-alcoholic fatty liver disease-related liver fibrosis and cardiovascular disease have a severe impact on the patient's prognosis and mortality rate. The American Diabetes Association's 2024 "Guidelines for the Standardized Management of Diabetes" put forward recommendations relevant to the screening, evaluation, treatment, and management of NAFLD in T2DM and prediabetic populations, as well as liver fibrosis. The important measures for decelerating liver inflammation and fibrosis progression and the risk of cardiovascular disease are based on improvements in lifestyle methods, weight loss, and blood sugar control.
Keyphrases
- liver fibrosis
- cardiovascular disease
- glycemic control
- type diabetes
- weight loss
- cardiovascular events
- cardiovascular risk factors
- clinical practice
- bariatric surgery
- risk assessment
- case report
- oxidative stress
- metabolic syndrome
- physical activity
- early onset
- roux en y gastric bypass
- body mass index
- gastric bypass
- combination therapy
- replacement therapy
- weight gain